Edaravone for treatment of early-stage ALS
- PMID: 28920880
- DOI: 10.1016/S1474-4422(17)30289-2
Edaravone for treatment of early-stage ALS
Comment in
-
Edaravone for treatment of early-stage ALS - Authors' reply.Lancet Neurol. 2017 Oct;16(10):772. doi: 10.1016/S1474-4422(17)30290-9. Epub 2017 Sep 12. Lancet Neurol. 2017. PMID: 28920878 No abstract available.
Comment on
-
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.Lancet Neurol. 2017 Jul;16(7):505-512. doi: 10.1016/S1474-4422(17)30115-1. Epub 2017 May 15. Lancet Neurol. 2017. PMID: 28522181 Clinical Trial.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
